Literature DB >> 18414826

[Expanding therapeutic reference ranges using dose-related reference ranges].

E Haen1, C Greiner, W Bader, M Wittmann.   

Abstract

Evidence-based therapeutic drug monitoring (TDM), which may be successfully employed to guide drug therapy in clinical routine, supplies all the information from laboratory determination of a drug concentration in a patient's blood specimen. This value is interpreted first of all in relation to a therapeutic reference range that must be established according to the same rules that are generally accepted for clinical studies aimed to license a new drug. The drug concentration may be furthermore interpreted in reference to a dose-related reference range. Thereby a signal is created to alert for individual abnormalities such as drug/drug interactions, gene polymorphisms that give rise to slow/rapid metabolizers, altered function of the excretion organs liver and kidneys by age and/or disease, compliance problems, a missing pharmacokinetic steady state, and even signal overlay in the laboratory analysis. We return all information available and clinical pharmacological comments to physicians who send specimens to our laboratory.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18414826     DOI: 10.1007/s00115-008-2471-9

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  31 in total

1.  Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders.

Authors:  B J McConville; L A Arvanitis; P T Thyrum; C Yeh; L A Wilkinson; R O Chaney; K D Foster; M T Sorter; L M Friedman; K L Brown; J E Heubi
Journal:  J Clin Psychiatry       Date:  2000-04       Impact factor: 4.384

2.  The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects.

Authors:  B Søgaard; H Mengel; N Rao; F Larsen
Journal:  J Clin Pharmacol       Date:  2005-12       Impact factor: 3.126

3.  Pharmacokinetics of haloperidol in psychotic patients.

Authors:  Y F Cheng; L K Paalzow; U Bondesson; B Ekblom; K Eriksson; S O Eriksson; A Lindberg; L Lindström
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients.

Authors:  M G Choc; F Hsuan; G Honigfeld; W T Robinson; L Ereshefsky; M L Crismon; S R Saklad; J Hirschowitz; R Wagner
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

5.  An evaluation of maprotiline intravenous kinetics and comparison of two oral doses.

Authors:  K P Maguire; T R Norman; G D Burrows; B A Scoggins
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

6.  Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man.

Authors:  E Snoeck; A Van Peer; M Sack; M Horton; G Mannens; R Woestenborghs; R Meibach; J Heykants
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

7.  Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis.

Authors:  O Spigset; S Hägg; B Stegmayr; R Dahlqvist
Journal:  Eur J Clin Pharmacol       Date:  2000-12       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of mirtazapine.

Authors:  C J Timmer; J M Sitsen; L P Delbressine
Journal:  Clin Pharmacokinet       Date:  2000-06       Impact factor: 6.447

9.  Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.

Authors:  Suresh Mallikaarjun; Daniel E Salazar; Steven L Bramer
Journal:  J Clin Pharmacol       Date:  2004-02       Impact factor: 3.126

10.  Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.

Authors:  Julia Kirchheiner; Gunnar Müller; Ingolf Meineke; Klaus-Dieter Wernecke; Ivar Roots; Jürgen Brockmöller
Journal:  J Clin Psychopharmacol       Date:  2003-10       Impact factor: 3.153

View more
  5 in total

Review 1.  [Therapeutic drug monitoring in psychiatry. A brief summary of the new consensus paper by the task force on TDM of the AGNP].

Authors:  G Gründer; P Baumann; A Conca; G Zernig; C Hiemke
Journal:  Nervenarzt       Date:  2014-07       Impact factor: 1.214

Review 2.  [Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP].

Authors:  Stefan Unterecker; Gudrun Hefner; Pierre Baumann; Gerd Gründer; Niels Bergemann; Hans-Willi Clement; Andreas Conca; Jürgen Deckert; Katharina Domschke; Gabriel Eckermann; Karin Egberts; Manfred Gerlach; Christine Greiner; Ekkehard Haen; Ursula Havemann-Reinecke; Renate Helmer; Ger Janssen; Eveline Jaquenoud; Gerd Laux; Thomas Messer; Rainald Mössner; Matthias J Müller; Michael Paulzen; Bruno Pfuhlmann; Peter Riederer; Alois Saria; Bernd Schoppek; Georgios Schoretsanitis; Markus Schwarz; Margarethe Silva Gracia; Benedikt Stegmann; Werner Steimer; Julia C Stingl; Manfred Uhr; Sven Ulrich; Roland Waschgler; Gerald Zernig; Gabriele Zurek; Christoph Hiemke
Journal:  Nervenarzt       Date:  2019-05       Impact factor: 1.214

Review 3.  [Basic principles of therapy with neuropsychotropic drugs].

Authors:  G Gründer; T Veselinović; M Paulzen
Journal:  Nervenarzt       Date:  2012-09       Impact factor: 1.214

4.  Elevated clozapine serum levels in combination with perazine.

Authors:  M Fischer; S Unterecker; J Deckert; B Pfuhlmann
Journal:  Psychopharmacology (Berl)       Date:  2013-02-09       Impact factor: 4.530

Review 5.  [Drug-drug interactions: interactions between xenobiotics].

Authors:  E Haen
Journal:  Nervenarzt       Date:  2014-04       Impact factor: 1.214

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.